Pyrimethamine Elicits Antitumor Effects on Prostate Cancer by Inhibiting the p38-NF-κB Pathway

Pyrimethamine Elicits Antitumor Effects on Prostate Cancer by Inhibiting the p38-NF-κB Pathway

Since incurable castration-resistant prostate cancer (CRPC) inevitably develops following treatment with androgen deprivation therapy, there is an urgent need to devise new therapeutic strategies to treat this cancer. Pyrimethamine, an FDA-approved antimalarial drug, is known to exert an antitumor a...

Full description

Bibliographic Details
Main Authors: Xumin Zhou, Jinming Zhang, Xiaoping Hu, Peiqing He, Jianyu Guo, Jun Li, Tian Lan, Jumei Liu, Lilan Peng, Hua Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Pharmacology
Subjects:
prostate cancer
pyrimethamine
antitumor
p38 MAPK
p65/NF-κB
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00758/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.00758/full

Similar Items